Lupin Limited has announced the launch of Topiramate Extended-Release Capsules in the United States. The capsules are available in 25 mg, 50 mg, 100 mg, and 200 mg strengths. This launch follows the approval of Lupin's Abbreviated New Drug Application (ANDA) by the U.S. Food and Drug Administration (FDA). These extended-release capsules are bioequivalent to the reference listed drug, Trokendi XR® Extended-Release Capsules, manufactured by Supernus Pharmaceuticals, Inc. The medication is indicated for several seizure treatments in patients aged 6 years and older, as well as for the preventive treatment of migraine in patients aged 12 years and older. The U.S. market for Topiramate Extended-Release Capsules has an estimated annual sale of USD 164 million, based on IQVIA data as of December 2025.
